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Abstract
Background—Pre-Exposure Prophylaxis (PrEP) for HIV prevention is a novel biomedical 
prevention method. We have previously modeled PrEP during rectal SHIV exposures in macaques 
and identified that SHIV-specific T cell responses were induced in the presence of antiretroviral 
drugs, an observation previously termed T cell chemo-vaccination. This report expands those 
initial findings by examining a larger group of macaques that were given oral or topical PrEP 
during repeated vaginal virus exposure.
Methods—Thirty-six female pigtail macaques received up to 20 repeat low-dose vaginal 
inoculations with wild type (WT) SHIVSF162P3 (n=24) or a clonal derivative with the tenofovir 
K65R drug resistant mutation (n=12). PrEP consisted of oral Truvada (n=6, WT), tenofovir 
vaginal gel (n=6, K65R), or tenofovir intra-vaginal ring (n=6, WT). The remaining animals were 
PrEP-inexperienced controls (n=12, WT; n=6, K65R). SHIV-specific T cells were identified and 
characterized using IFNγ ELISPOT and multi-parameter flow cytometry.
Results—Of nine animals that were on PrEP and remained uninfected during WT SHIV vaginal 
challenges, eight (88.9%) developed virus-specific T cell responses. T cells were in CD4 and CD8 
compartments, reached up to 4,900 IFNγ producing cells per million PBMCs, and primarily pol 
directed. In contrast, the replication impaired K65R virus did not induce detectable T cell 
responses, likely reflecting the need for adequate replication.
Conclusion—Virus-specific T cell responses occur frequently in oral or topical PrEP-protected 
pigtail macaques after vaginal exposure to WT SHIV virus. The contribution of such immune 
responses to protection from infection during and following PrEP warrants further investigation.
*Correspondence: Dr. Ellen Kersh, CDC, 1600 Clifton Road NE, Mailstop A25, Atlanta, GA 30333. egk6@cdc.gov, Tel: 
404-639-2728. 
Author Contributions: Designed the study: ENK, TST; Acquired data: TST, KB, WL, RA; Analyzed and interpreted results: TST, 
KB, WL, RA, EK, JMN; provided samples: PS, JR, SS, CD, GGL, WH; Performed statistical analysis: TST, ENK, DLH; Wrote 
manuscript: TST and ENK. All authors read and approved the manuscript.
Conflicts of interest: The authors declare no conflicts of interest
Part of the data was presented at the 19th Conference on Retrovirus and Opportunistic Infections (CROI 2012), Seattle, WA, USA.
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the 
Centers for Disease Control and Prevention.
HHS Public Access
Author manuscript
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 August 01.
Published in final edited form as:














SHIV; pre-exposure prophylaxis; T cell immune response; exposed uninfected; pig tail macaques
Introduction
Four human clinical trials (iPrEX, CDC TDF2, Partner PrEP, Bangkok Tenofovir Study) 
have provided proof of concept for use of Pre-Exposure Prophylaxis (PrEP) against HIV-1 
infection by men who have sex with men, heterosexually active men and women and 
intravenous drug users1–4. And, Truvada, the combination of the antiretroviral drugs 
Emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) has been licensed by the US 
Food and Drug Administration as the first PrEP drug5–7. PrEP continues to be studied to 
improve adherence and implementation, among other follow up studies8,9.
We have previously examined if immune responses are affected by the use of PrEP10–12, 
modeling PrEP in rhesus macaques. We showed that rectal SHIV exposure with repeat low-
doses (RLD) in the presence of oral PrEP can result in the development of SHIV-specific 
adaptive T cell immune responses in protected rhesus macaques, an effect previously termed 
chemo-vaccination10. Our previous report was based on studying four macaques, of which 
two developed measurable anti-SHIV T cell responses. It is not known if virus-specific T 
cell priming is a common phenomenon during PrEP. To better understand these T cells and 
their induction, here we examined a larger cohort of macaques, and asked whether T cell 
priming occurs frequently, and if it develops in female pigtail macaques during vaginal 
SHIV exposure with topical or systemic PrEP.
Understanding the mechanism of, and eliciting cell-mediated mucosal immune response 
against HIV is one focus of current vaccine strategies13–15. For instance, attenuated vaccine 
strains of SIV have been shown to elicit CD8+ T cell responses that protect and control SIV 
infection in macaques14,15. Our previous work has shown that T cell responses that develop 
in macaques during rectal SHIV challenges with oral Truvada use consisted of CD4+ and 
CD8+ SHIV-specific T cells10. It is not clear whether such immune responses have any 
consequences for or confer any advantage during subsequent virus exposures. Ideally, 
immunity would contribute to the efficacy of PrEP by induction of antiviral and cytotoxic 
CD8+ T cells and helper CD4+ T cells. T cell priming could improve immunity, should 
breakthrough infections occur, by increasing antiviral cytokines and immune responses 
against a possibly attenuated virus by the presence of suppressive antiretroviral drugs11,16. It 
is also possible, however, that T cell priming might create immune activated cells that are 
highly susceptible to subsequent infection.
The contribution of virus-specific T cell responses to the efficacy of PrEP and the 
mechanisms by which the T cell responses occur are at present not clear. In this report, we 
sought to further characterize the responses to learn more about their frequency of 
occurrence, magnitude, epitope specificity, and immune-phenotypic features. We 
specifically asked how frequently they occur, using a larger cohort of macaques than 
previously studied. We also examined whether virus-specific T cell responses on PrEP are 
induced after vaginal route of virus exposure as opposed to our previous report using rectal 
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virus exposures. Furthermore, we investigated if they occur in pigtail macaques which differ 
from the rhesus macaque species that we previously studied, and using different PrEP 
modalities that included oral and topical drug formulations. Finally, because the mechanisms 
of T cell induction are unknown, but could be dose dependent, could involve antigen-
presentation through non-classical pathways that are independent of viral replication, and 
because persons receiving PrEP may be exposed to HIV variants with drug-resistance 
mutations, we evaluated the virus-specific responses in animals exposed to a replication-
impaired virus with a K65R mutation17, given at a higher dose than the wild type virus.
Methods and Materials
Ethics statement
The Institutional Animal Care and Use Committee (IACUC) of the Center for Disease 
Control and Prevention (CDC) approved all the macaque procedures for the studies. 
Macaques were housed at the CDC under the full care of CDC veterinarians in accordance 
with the Guide for the Care and Use of Laboratory Animals of the National Institute of 
Health18. All procedures were done under anesthesia using ketamine and efforts were made 
to minimize suffering, improve housing conditions and to provide enrichment opportunities.
PrEP efficacy studies with RLD vaginal SHIV exposures in pigtails
The Repeat-Low dose (RLD) mucosal virus exposure model used in this study involves 
repetitive mucosal exposure using low doses of virus (10 to 50 TCID50, equivalent to 105–
106 virus particles), which approximates viral loads observed in semen during acute HIV-1 
infection19. The RLD model mimics repeated sexual exposures to the virus during high-risk 
sexual activity19. Thirty-six female pigtail macaques were enrolled in three different studies 
designed to evaluate the efficacy of PrEP. The intermittent oral Truvada PrEP study has 
been described20. Briefly, six pigtail macaques were in the PrEP-treated group receiving 
intermittent oral Truvada (given at 20 mg/kg of FTC and 22 mg/kg of TDF 24 h before and 
2 h after vaginal SHIV) and six were in the control group receiving placebo. Virus challenge 
consisted of RLD vaginal exposures of R5-tropic SHIVSF162P3 virus21, obtained through the 
NIH AIDS Reagent program, Germantown, MD. It was propagated at CDC in pigtail 
PBMCs, titrated and given to macaques once weekly for up to 18 challenges at a dose of 50 
TCID50. Twelve macaques were in the intra-vaginal ring-tenofovir (IVR-TFV) study: six 
with silicone IVRs (25 × 5 mm) containing four 15mg TFV pods/ring and six with placebo 
IVRs with blank pods as described previously22,23. The virus dose in the IVR-tenofovir 
study was also low (50 TCID50) administered twice weekly for up to 14 challenges. The 
vaginal tenofovir gel study with SHIVSF162P3-K65R virus included six pigtail macaques in 
the PrEP-treated and six in the control arms24. SHIVSF162P3-K65R virus has a K65R mutation 
in the reverse transcriptase enzyme, rendering the virus partially resistant to tenofovir17. 
SHIVSF162P3-K65R virus has 10-fold less infectivity compared to SHIVSF162P3, based on 
virus infectivity to particle ratio, described in25. Vaginal tenofovir gel (1%, delivering 30 mg 
tenofovir in a 3 mL volume) or a placebo gel were administered to the animals 30 minutes 
prior to vaginal virus challenges at an adjusted dose of 500 TCID50 SHIVSF162P3-K65R to 
compensate for lower infectivity, twice weekly for up to 20 challenges. SHIV infection was 
detected and monitored in all three studies using a previously described quantitative RT-
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PCR method26, with detection limit of the assay being 50 viral RNA copies/mL. Virus 
challenges were stopped once systemic SHIV infection occurred, here defined as detection 
of plasma SHIV RNA of at least 50 copies/ mL on two consecutive blood collections.
Detection of SHIV-specific T cells using IFN-γ ELISPOT assays
Freshly isolated peripheral blood mononuclear cells (PBMCs) obtained from the three 
studies at baseline, during virus challenges and post-challenge follow ups were used in 
ELISPOT assays. The IFN-γ ELISPOT assay for nonhuman primate PBMCs was described 
previously10. Briefly, MultiScreen-HA 96-well plates (EMD Millipore, Billerica, MA) were 
pre-incubated with 5ug/ml of anti-human IFNγ (BD Biosciences, San Diego, CA) overnight 
at 4°C. Next day, plates were blocked with complete RPMI medium for 1 h at 37°C. Plates 
were then washed with RPMI and 200,000 PBMCs per well were seeded and incubated with 
SHIV peptide pools (15-mers with 11 amino acid overlaps) at final concentrations of 
1.5ug/ml in the presence of 1.25ng/ml IL-15 (Sigma-Alderich, St. Louis, MO). The 
following peptide pools obtained through the NIH AIDS Reagent Program (Germantown, 
MD) and their respective catalogue numbers shown in brackets, were used. Full length gag 
(#6204), pol (#6443), nef (#8762), vpr (#6449) and vif (#6205) were derived from 
SIVmac239. The env peptide pools (#7619) were from SHIVSF162P3, which harbors HIV-1 
subtype B envelope. Tat (#5138) and rev (#6445) peptide pools were from HIV-1 consensus 
B peptides. Staphylococcus aureus Enterotoxin B (SEB) peptide and Ebola virus-derived 
peptides (EB) served as positive and negative (mock peptide) controls, respectively, as 
previously described27. After 36 h stimulation with the peptide pools, plates were washed 
and biotinylated anti-human IFN-γ antibody (MABTECH, Mariemont, OH), horse radish 
peroxidase conjugated streptavidin (BD Biosciences, San Diego, CA) and Nova red color 
substrate (Vector Labs, Burlingame, CA) were used sequentially to stain and detect IFN-γ 
secretions. The IFN-γ spot forming units (SFUs) were enumerated using a S5 Core Analyzer 
(Cellular Technology, Shaker Heights, OH). SHIV-specific T cells responding to each 
peptide pool were determined as SFUs/106 PBMCS after subtracting the values obtained by 
mock peptide stimulation.
Multi-parameter flow cytometry
PBMCs archived and available at one-time point from the intermittent oral Truvada study 
were analyzed by flow cytometry for surface and intracellular markers. For the PrEP-
protected group, PBMCs that showed the highest SHIV-specific T cell responses (identified 
by IFN-γ ELISPOT) were analyzed, and in the control treated-infected group, PBMCs at the 
time of peak viremia were analyzed. PBMCs were limiting and were unavailable at other 
time points or from the IVR-tenofovir and vaginal tenofovir gel with SHIVSF162P3-K65R 
studies. Multi-parameter flow cytometer techniques are described elsewhere14,28. Briefly, 
frozen PBMCS were thawed and allowed to rest overnight in a cell culture at 37°C with 5% 
CO2. Next day, cells were washed and transferred to round bottom 96-well plates (Corning 
Life Sciences, Tewksbury, MA). Cells were stimulated for 6 h at 37°C with peptide pools of 
gag or pol, using the same peptide pools as used in ELISPOTs at 1.5ug/ml final 
concentration in the presence of GolgiStop Protein Transport Inhibitor (BD Biosciences, San 
Diego, CA). EB and SEB peptides served as negative and positive antigenic stimulation 
controls. Cells were then stained using extracellular surface marker antibodies. 
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Permeabilization and staining for intracellular cytokines followed using the BD Cytofix/
Cytoperm kit according to the manufacturer’s instruction (BD Biosciences, San Diego, CA). 
The following antibodies were purchased from BD Biosciences with clone names indicated 
in the parenthesis. Anti-CD3 Pacific Blue (SP34-1), anti-CD4-V500 (L200), anti-CD8 APC-
Cy7 (SK1), anti-CD28-PE-CF594 (CD28.2), anti-IL-2 APC (MQ1-17H12), anti-TNFα 
Alexa F700 (MAB11), anti-IFN-γ PE-Cy7 (B27) and MIP-1β PE (D21-1351). Anti-CCR7-
FITC (050503) was from R and D Systems (Minneapolis, MN). Data were acquired using 
LSR II Flow Cytometer (BD Biosciences, San Diego, CA) and analyzed using FlowJo 
software version 7.6.5 (Tree Star, San Carlos, CA).
Statistical analysis of anti-viral T cell respnses
For our first analysis method, we used the following definition for virus-specific T cell 
responses during PrEP: SHIV-specific T cell responses that occurred in PrEP-treated 
macaques without systemic SHIV infection at the time, and that were above a cut-off of all 
36 study animals’ mean IFN-γ SFU baseline responses plus three times the standard 
deviation, as previously done10. This resulted in an IFN-γ SFU cut-off value of 907/106 
PBMCs. As a second analysis method, and when indicated, we also studied SHIV-specific T 
cell responses in PrEP-treated and in untreated animals, even if they did not meet our above 
cut-off for virus-specific T cell responses during PrEP. These responses were calculated 
after subtracting the values obtained by mock peptide stimulation on the same day, to 
exclude non-specific responses. Median SFU values were calculated for each monkey from 
its multiple measures taken over time and either Mann-Whitney tests were performed to test 
for statistical differences between groups or paired t-test were performed for comparisons to 
baseline values using GraphPad software.
Results
Virus-specific T cell responses develop in systemic or topical PrEP-experienced, exposed 
uninfected pigtails
To evaluate whether virus-specific T cell responses are induced, we examined nine 
macaques that remained uninfected after receiving PrEP in oral form (n=6, oral Truvada)20, 
or topically delivered (n=3, IVR-tenofovir)22 during 18 or 14 RLD vaginal challenges with 
wildtype SHIVSF162P3, respectively. Three PrEP-treated animals that became wildtype 
SHIVSF162P3-infected during the studies and two animals that were not PrEP-experienced 
and remained uninfected were also evaluated. SHIV-specific T cell responses were 
determined using IFN-γ ELISPOT assays. Assays were performed on PBMC specimens 
collected at baseline (before start of virus challenges), weekly during virus challenges and as 
a follow up after completion of virus challenges. Figure 1 shows representative data of T 
cell responses in an infected control macaque shown for comparison (Fig. 1A, PrEP-
inexperienced), in a PrEP-treated macaque with virus-specific T cell responses (Fig. 1B), 
and in two PrEP- inexperienced control macaques that remained uninfected despite virus 
challenges and despite intermittently detected virus blips that did not result in systemic 
infection (Fig. 1C, D). SHIV-specific T cells were expressed as total SFUs per 106 PBMCs 
by adding SFU responses obtained with stimulation by individual SHIV peptide pools that 
spanned the full proteome of SHIV, and are depicted in black bar graphs scaled on the left y-
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axes. To rigorously distinguish virus-specific T cell responses from low-level anti-SHIV T 
cell responses in the analyses shown in Figure 1, we applied a strict cut-off value based on 
mean baseline responses of all 36 macaques involved in this study and three standard 
deviations (dotted line in Fig. 1). In the examples shown in Fig. 1B, the PrEP-experienced 
uninfected macaque had evidence of virus-specific T cell responses on five occasions. The 
first uninfected macaque without PrEP treatment did not have T cell responses above the 
cut-off, i.e., 907/106 IFN-γ SFU (Fig. 1C), and the other had three (Fig. 1D).
Virus-specific T cell responses in the representative macaque shown in Fig.1B started after 
four exposures and were intermittently observed throughout the 18 weeks of virus 
challenges. They were detectable for up to three weeks following termination of virus 
challenges, i.e. last in study week 21. T cell responses reached 3,371 SFU/ 10^6 in the 
example shown in Fig. 1B. The other seven uninfected animals with T cell responses had 
comparable responses. A response of 4,900 IFNγ producing cells per million PBMCs was 
the strongest response observed in a PrEP-treated, uninfected animal (data not shown). T 
cell responses could thus reach the magnitude of T cell responses in infected animals (e.g., 
in Fig. 1A), although many lower responses continued to occur even after initial virus-
specific T cell responses above cut-off were observed (e.g., in Fig. 1B, study week 11).
Eight of the nine PrEP-protected macaques had detectable virus-specific responses (five in 
the intermittent oral Truvada and three in IVR-tenofovir studies, data summarized Table 1). 
One PrEP-treated, uninfected animal (in the oral Truvada group) did not meet the criteria for 
virus-specific T cells because its’ T cell responses remained below our cut-off in this 
analysis. In summary, we found that virus-specific T cell responses during PrEP develop in 
a majority of exposed-uninfected monkeys (n=8/9 (88.9%)).
We also examined the ability of a mutant, replication-impaired virus to induce virus-specific 
T cell responses during PrEP. We examined induction of SHIV-specific T cell responses in 
animals on topical PrEP with vaginal tenofovir gel and challenged with a drug-resistant 
virus containing the K65R point mutation (SHIVSF162P3-K65R)24. This mutation reduces the 
replicative capacity of the virus17. To adjust for the partial replication impairment, virus 
exposures were performed at 10 times the original dose for wild type virus (500 TCID50 
instead of 50 TCID50). Despite the larger inoculum, none of the five PrEP-treated uninfected 
macaques developed virus-specific T cell responses (0/5 [0%]). This was in contrast to eight 
of nine PrEP-treated, uninfected, WT-SHIV exposed macaques (Table 1). We found that the 
IFN-γ-ELISPOT T cell responses (SFUs) for all the five animals were below cut-off; 
representative data of one animal are shown in Fig.1E. This indicated that SHIV with K65R 
mutation, although infectious, is not as efficient as wildtype virus in inducing SHIV-specific 
T cell responses (P=0.003, Fisher’s exact test to compare the two proportions).
Induction of T cell responses over baseline responses following virus exposures
As an additional method to document induction of T cell responses over baseline we 
examined all anti-SHIV T cell responses after virus exposures, not only responses in PrEP-
treated animals that were intermittently above our rigorous cut-off. This was done because 
application of the rigorous cut-off based on mean group baseline response plus three 
standard deviations, as done in Fig 1, could obscure small but nevertheless significant T cell 
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response amplifications. The analyses were still done after subtraction of responses to 
unrelated, mock peptide pools, another safeguard against evaluating non-specific responses. 
Fig. 2 shows the distributions of median anti-SHIV T cell responses from all longitudinal 
measures per animal, at baseline and after virus exposure. At baseline, we observed a 
median 156 SFUs per 106 PBMCs, calculated from all 24 animals that received wildtype 
virus. In PrEP-treated animals, median SFUs were 411 per 106 PBMCs after virus exposure 
(Fig.2). The difference over their own baseline value was statistically significant in these 
animals (p=0.01, paired, two-tailed t-test), indicating induction of T cell immunity due to 
SHIV exposure. Note that this group included T cell responses of 12 monkeys (nine PrEP-
treated and remaining uninfected, and three PrEP-treated prior to developing breakthrough 
infection). We also examined animals that did not receive PrEP. This group included the two 
monkeys that remained uninfected and six that had T cell responses prior to developing 
infection, although the time span for T cell induction was often brief (example, SFU 
response at week 4 of Fig.1A). Four monkeys had become infected so quickly that no 
ELISPOTS were performed prior to infection. The median T cell response was 501 SFUs 
per 106 PBMCs in this group; the difference was not statistically significant over their 
baseline (p=0.17, paired, two-tailed t-test). Fig. 2 also shows median T cell responses after 
infection in PrEP-treated and untreated animals. Data were obtained from a minimum of 
five, and up to 12 IFNgamma-ELISPOT assays performed after infection. As expected, 
these responses were robust and were a median of 1774 and 1414 SFUs per 106 PBMCs, 
respectively.
Pol epitope focus of virus-specific T cell responses during PrEP
There is a well-documented relationship between virus-specific CD8+ T cell response and 
control of SIV/SHIV/HIV infection. Presence of MHC class I restricted CD8+ T cell 
responses has been positively correlated with control of acute viremia and disease 
progression in monkeys29 and humans30,31. We therefore characterized to which SHIV 
epitopes virus-specific T cell responses during PrEP were focused (Fig.3). The distributions 
of env and accessory protein-specific responses were not different in the infected group 
(filled black circles) relative to the PrEP-treated, uninfected group (open circles). Gag 
responses were higher in the infected than the PrEP-treated, uninfected group (p=0.02, two-
tailed Mann-Whitney test). However, pol-specific responses were substantially more 
dominant in the PrEP-treated, uninfected group than the infected group (p=0.01, two-tailed 
Mann-Whitney Test, Fig.3).
Characteristics of T cell responses in uninfected macaques during PrEP
To further examine the nature of virus-specific T cell responses during PrEP, we 
characterized surface and functional markers by multi-parameter flow cytometry. Sample 
availability was a limiting factor and only PBMCs from one time of the oral Truvada study 
could be obtained and analyzed, which was not sufficient for statistical analysis. PBMCs 
were obtained from the week of highest IFN-γ SFU responses in the intermittent oral 
Truvada-treated monkeys; and from peak viremia for the infected (PrEP-inexperienced) 
control group. CD3+ T lymphocytes in the PrEP-treated group had a similar cytokine 
secretion profile as T cells in infected animals in response to gag or pol peptide stimulations 
(Fig.4A and Fig.4B, respectively). Poly-functionality of T cells, the ability to secrete more 
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than one cytokine, is an immunological quality that correlates with control of HIV/SIV 
disease progression32,33. We therefore looked into the poly-functionality of T cells in PrEP-
treated, uninfected macaques, and infected controls groups. SHIV-specific T cells producing 
any two, three or four of the cytokines IFN-γ, MIP-1α, IL-2 and TNF-α were similarly 
present in the two groups (Fig.4C). The majority of SHIV-specific T cells in both groups 
were single cytokine producers, followed by two, three and four cytokine producers (Fig.
4C).
SHIV-specific cytokine producing CD4+ and CD8+ T cells were present in both groups 
(Fig. 4D). For instance, 39.0% in the PrEP-treated, uninfected group and 35.3% in the 
infected group were pol-specific CD4+ T cells (Fig.4D). Pol-specific CD8+ T cells were 
54.4% for the PrEP-treated, uninfected group and 55.0% for the infected group. Similar 
results were obtained for gag-specific CD4+ and CD8+ T cells (Fig.4D).
Finally, SHIV-specific cytokine producing CD4+ and CD8+ T cells in the PrEP-treated, 
uninfected, and infected groups were analyzed for central memory cells (CM= CCR7+, 
CD28+) and effector memory cells (EM1+EM2, where EM1= CCR7−, CD28+, and 
EM2=CCR7−, CD28−) (Fig.4E and Fig4F). Overall, CD4 memory cells were predominantly 
CM and CD8 memory cells were predominantly EM. Similar antigen-specific effector 
memory and central memory phenotypes were observed in both groups. For instance, pol-
specific CD8+ T cells with effector memory phenotype were 81.8% in the PrEP-treated, 
uninfected and 77.1% in infected control groups (Fig.4F). Results were similar for central 
memory phenotype and gag-specific memory cells (Fig.4E and 4F). In sum, the poly-
functionality, CD8+, CD4+ and memory phenotypes of SHIV-specific cytokine secreting T 
cells of PrEP-treated, uninfected macaques were similar to SHIV-specific T cells that 
develop during infection.
Discussion
We and others previously reported that T cell priming or so-called “chemo-vaccination” 
occurs during RLD mucosal virus challenges and with the use of oral or topical PrEP in a 
small number of macaques12,10,34. The current study expands these earlier isolated 
observations by showing that virus-specific T cell responses can develop in eight of nine 
exposed uninfected macaques during vaginal virus challenges while on PrEP. Hence, we 
now affirm that virus-specific T cell responses during PrEP can be a frequent phenomenon 
in exposed uninfected monkeys. It remains to be determined whether the vaginal route of 
virus challenge is more effective than the rectal route in inducing the responses. 
Furthermore, an important question relevant to PrEP development remains unanswered, i.e., 
if animals with these responses are more or less susceptible to subsequent infection. It will 
be necessary to design macaque experiments specifically to answer these questions, while 
our current results stem from left-over samples from studies designed to test PrEP 
efficacy20–24.
PrEP constitutes a novel usage of antiretroviral drugs for HIV-1 prevention in high-risk 
groups1–7,35, and ongoing and future clinical trials will address issues like improving the 
adherence and implementation of PrEP8,9,36. Virus-specific T cell responses during PrEP 
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might also be a common occurrence in humans, and it may enhance protection from 
infection, alter the course of breakthrough infection, or increase infection risk. So far, very 
few studies have addressed the effect of PrEP drugs on HIV immunity16,37, perhaps owing 
to the difficulty of getting adequate and timely samples from exposed uninfected individuals 
while on PrEP. For instance, a study by Mureithi and colleagues16 showed that in 
individuals infected despite vaginal tenofovir gel use as PrEP, HIV-1 immunity was 
modulated by better preservation of gag-specific IFN-γ secreting CD4+ T cells than controls 
that became infected without vaginal gel use. Melchjorsen and colleagues on the other hand, 
found that HIV-uninfected human PBMCs treated in vitro with tenofovir have altered 
secretion of the cytokines IL-10 and IL-12, thereby affecting the overall inflammatory 
response of treated PBMCs37. Thus, further studies are required to understand if virus-
specific T cell responses during PrEP occur in humans and to decipher the immunological 
effects of tenofovir and other PrEP agents in exposed uninfected PrEP-experienced 
individuals.
The mechanism by which virus-specific T cell responses during PrEP occur is unknown. 
The observation is somewhat reminiscent of exposed uninfected humans38,39, 40. T cell 
responses developing with and without PrEP may be similar in nature, but not in magnitude 
in our model. Responses in exposed uninfected control macaques remained below the 
threshold for statistical significance (Fig. 2), or were of lower magnitude than in PrEP-
treated exposed uninfected macaques (Fig. 1C, D). It is possible that anti-retroviral drugs 
affect the responses in ways currently not fully understood; this merits further investigation 
in our model. It is also possible that PrEP-treatment allows T cells to develop more 
efficiently than in other exposed uninfected individuals, because individuals on PrEP may 
experience more initial virus replication (see below), stay uninfected for longer, and 
experience more virus exposures without infection, and thus have more opportunities for T 
cell induction. Presumably, the presence of virus at mucosal tissues with low levels of 
replication owing to inhibiting antiretroviral drugs can lead to activation of antigen 
presenting cells and immune processing of viral fragments without productive infection, the 
end result being stimulation of the adaptive virus-specific T cell responses. Interestingly, we 
noted that despite the use of a larger viral inoculum, virus-specific T cell responses during 
PrEP were not observed in monkeys repeatedly exposed to a virus containing the K65R 
mutation in its reverse transcriptase gene. Our earlier works have shown that the K65R 
mutation results in reduced replication and viral fitness17,25. Induction of virus-specific T 
cell responses did not occur in this group probably because the virus was replication 
impaired. Thus, antigenic exposure resulting from some form of viral replication rather than 
from the viral inoculum might be critical to induce T cells during PrEP. Likewise, the 
presence of T cells directed to accessory proteins of SHIV (as seen in our study, Figure 3) 
are consistent with replication playing a role41. Studying tissue resident antigen-presenting 
cells and mucosal T cells for occult infections might help to understand the mechanism of T 
cell priming during PrEP. Our experiments were limited by having only specimens of 
opportunity available for study. The impact of virus dose and replication on T cell priming 
warrants further investigation in experiments specifically designed to address these 
questions, and would best be addressed by including different doses of wildtype, replication-
competent virus, and by collecting mucosal specimens for analysis.
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Both our current and previous studies10 showed that the SHIV-specific T cells in uninfected, 
PrEP-treated macaques are comprised of polyfunctional CD8+ and CD4+ T cells. Thus, 
there was potential induction of CD8+ T cells capable of controlling acute HIV or SHIV 
infection42–45, but also of CD4+ T cells which might create a large pool of target cells for 
infection46,47. We observed a shift toward more pol-specific T cells in the PrEP-treated, 
uninfected group than in the infected group. A similar tendency has been reported in our 
earlier study10. Presence of gag-specific CD8+ T cells correlates with viral control in long-
term non-progressors30,31,48. However, pol-specific MHC class I restricted CD8+ T cell 
responses have also been shown to recognize infected cells in ex vivo co-culture models49. 
In this regard, future studies of PrEP-mediated immunity might reveal interesting insights as 
to why pol-specific T cells are preferentially induced, where the exact epitopes recognized 
map in each animal, and whether they have any beneficial role. As previously reported10, we 
found no evidence for B cell induction in PrEP-treated, uninfected macaques in our present 
study.
In summary, our study confirmed that the induction of SHIV-specific T cells in exposed 
uninfected monkeys during repeated mucosal virus challenges in the presence of PrEP, is a 
common occurrence. Both oral and topical PrEP modalities were able to induce systemic 
responses. Replication-impaired virus failed to induce virus-specific T cell responses, 
suggesting that viral replication is critical for their induction. It remains of interest to 
examine if virus-specific T cell responses occur in humans taking PrEP. Ultimately, the role 
virus-specific T cells have on the efficacy of PrEP and antiretroviral therapy should be 
studied in broader detail.
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Figure 1. Schematic representation of SHIV-specific T cell responses measured by IFN-γ 
ELISPOT assay for the intermittent oral Truvada and vaginal tenofovir gel studies with 
repeated vaginal SHIVSF162P3 and SHIVSF162P3-K65R virus challenges, respectively
(A) Data of representative control (no PrEP) infected macaque from the intermittent oral 
Truvada study are shown. Once-weekly virus challenges were stopped after the 6th challenge 
when the animal was confirmed infected. The line curve depicts viral loads scaled 
logarithmically on the right Y-axes. (B) Data of a representative monkey that was protected 
by intermittent oral Truvada and developed virus-specific T cells during 18 once-weekly 
virus challenges are shown. (C, D) Data from the two exposed, uninfected macaques 
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participating in the intra-vaginal ring study is shown. (E) Data of a representative monkey 
with lack of SHIV-specific T cell responses during 20 virus challenges with 
SHIVSF162P3-K65R mutant virus in the presence of vaginal tenofovir gel are shown. The 
black bar graphs, scaled on the left Y-axes, represent SHIV-specific T cell responses 
expressed as IFN-γ total SFUs per million PBMCs. X-axes show weeks relative to virus 
challenges, where week 1 was the start of virus challenges. The dotted horizontal lines on 
each graph show the rigorous cut-off point for virus-specific T cell responses during PrEP 
(SFU 907/106 PBMCs).
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Figure 2. Amplification of SHIV-specific T cell responses in macaques during RLD vaginal virus 
exposures with intermittent oral Truvada or IVR-tenofovir studies
IFN-γ total SFUs are shown for all the 24 monkeys enrolled in oral Truvada and IVR-
tenofovir studies at baseline and all time points examined. Median SFUs of each monkey are 
represented by the symbols and median SFUs of each group by horizontal lines, without 
application of a cutoff value. SFUs of the control group (no PrEP, exposed uninfected) show 
responses of eight monkeys (two monkeys that remained uninfected and six that had T cell 
responses prior to developing infection). SFUs of the PrEP-treated exposed uninfected group 
included responses of 12 monkeys (nine monkeys that were on PrEP and remain uninfected, 
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and three prior to developing breakthrough infection). For the infected group, the SFUs are 
shown of 10 PrEP-inexperienced (control) monkeys that got infected. Two tailed, paired t-
tests were performed to test for statistical significance (p values), using only the baseline 
values from each group for comparison.
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Figure 3. Epitope focus of virus-specific T cell responses during PrEP
Gag, env, pol and accessory protein (nef, vpr, vif, rev and tat combined)-specific IFN-γ 
SFUs in the intermittent oral Truvada and IVR-tenofovir studies were analyzed for the eight 
animals with T cell responses during PrEP and 10 infected monkeys, depicted in open and 
black circles respectively. Only responses above the cut-off were used (907 SFU/106 
PBMCs). Percentages of peptide-specific responses were expressed relative to the total 
summated SFU responses obtained by antigenic stimulation with individual SHIV-specific 
peptide pools spanning the full SHIV proteome. Each circle represents the median 
percentage of each animal and the horizontal lines show the percentage median of each 
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group. Two-tailed Mann Whitney test was performed on the percentage medians to test for 
statistical significance (p values).
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Figure 4. Characterization of virus-specific T cell responses during PrEP by multi-parameter 
flow cytometry
Archived PBMCs from five uninfected macaques in the intermittent oral Truvada study 
were obtained during the week of highest SHIV-specific T cell ELISPOT response, and for 
the infected animals (PrEP-inexperienced controls) at the week of peak viremia. (A) and (B) 
show median percentages of CD3+ T cells that were able to produce any of the cytokines 
IFN-γ, MIP-1β, IL-2 and TNF-α in response to gag (A) or pol (B) peptide stimulation. 
“Any” refers to producing any of the four cytokines (IFN-γ or MIP-1β or IL-2 or TNF-α) 
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but not necessarily simultaneously. (C) Poly-functionality of responses. Flow-cytometric 
data of SHIV-specific T cells to simultaneously produce multiple cytokines were analyzed 
using Boolean and combined gating strategies. The average percentage of any single, two, 
three, and all four cytokines producing CD3+ cells following gag or pol antigenic 
stimulation is shown for the two groups. (D) CD4+ and CD8+ phenotyping of SHIV-
specific cytokine producing CD3+ T cells. The median percentages of gag or pol-specific 
CD3+ T cells that were either CD4+ or CD8+ are shown for the two groups. (E) and (F) 
show phenotyping of cytokine producing SHIV-specific CD4+ and CD8+ T cells in effector 
memory (EM1=CCR7− and CD28+ and EM2=CCR7− and CD28−) and central memory 
(CM= CCR7+ and CD28+) subsets.(E) shows CD4+ and (F) shows CD8+ SHIV specific 
memory T cells. Medians of percentages are shown for the PrEP-treated, uninfected, and 
infected control groups.
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Table 1
Development of virus-specific T cells with oral or topical PrEP modalities
Pigtail macaques that underwent different PrEP efficacy studies using RLD virus challenge model were 
assessed for development of virus-specific T cell responses. WT virus (SHIVSF162P3) was used for intermittent 
oral Truvada and IVR-tenofovir studies, and the K65R mutant (SHIVSF162P3-K65R) for vaginal tenofovir gel 
study.











Intermittent oral Truvada (n=6 treated, n=6 
controls) reference20
SHIV 162p3, WT (50 TCID50) N=6
18 challenges
5 of 6
IVR-tenofovir (n=6 treated, n=6 controls) 
reference22
SHIV 162 p3, WT (50 TCID50) N=3
14 challenges
3 of 3
Vaginal tenofovir gel (n=6 treated, n=6 
controls), reference24
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